Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anjan Thakurta

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
The FEBS Journal|May 21, 2026
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myelomaMaria-Cynthia Fuentes-Lacouture, Devi Nandana, Karthik Ramasamy, et al.
Oncotarget|July 28, 2021
Developing next generation immunomodulatory drugs and their combinations in multiple myelomaAnjan Thakurta, William E Pierceall, Michael D Amatangelo, et al.
Cells|January 30, 2020
Prognosis, Biology, and Targeting of <i>TP53</i> Dysregulation in Multiple MyelomaErin Flynt, Kamlesh Bisht, Vinidhra Sridharan, et al.
Nature Biotechnology|July 2, 2021
Nanopore sequencing of single-cell transcriptomes with scCOLOR-seqMartin Philpott, Jonathan Watson, Anjan Thakurta, et al.
Frontiers in Genetics|February 28, 2022
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine PathwaysKubra Karagoz, Matthew Stokes, María Ortiz-Estévez, et al.
BMC Medical Genomics|December 19, 2021
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysMaría Ortiz-Estévez, Fadi Towfic, Erin Flynt, et al.
American Journal of Hematology|October 2, 2023
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemiaMaciej W Garbowski, Manuel Ugidos, Alberto Risueño, et al.
Haematologica|February 22, 2020
Differential RNA splicing as a potentially important driver mechanism in multiple myelomaMichael A Bauer, Cody Ashby, Christopher Wardell, et al.
Blood|August 19, 2022
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMMNicholas Stong, María Ortiz-Estévez, Fadi Towfic, et al.
Leukemia & Lymphoma|June 12, 2019
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)Anna Kalff, Tiffany Khong, Sridurga Mithraprabhu, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
The FEBS Journal|May 21, 2026
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myelomaMaria-Cynthia Fuentes-Lacouture, Devi Nandana, Karthik Ramasamy, et al.
Oncotarget|July 28, 2021
Developing next generation immunomodulatory drugs and their combinations in multiple myelomaAnjan Thakurta, William E Pierceall, Michael D Amatangelo, et al.
Cells|January 30, 2020
Prognosis, Biology, and Targeting of <i>TP53</i> Dysregulation in Multiple MyelomaErin Flynt, Kamlesh Bisht, Vinidhra Sridharan, et al.
Nature Biotechnology|July 2, 2021
Nanopore sequencing of single-cell transcriptomes with scCOLOR-seqMartin Philpott, Jonathan Watson, Anjan Thakurta, et al.
Frontiers in Genetics|February 28, 2022
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine PathwaysKubra Karagoz, Matthew Stokes, María Ortiz-Estévez, et al.
BMC Medical Genomics|December 19, 2021
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysMaría Ortiz-Estévez, Fadi Towfic, Erin Flynt, et al.
American Journal of Hematology|October 2, 2023
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemiaMaciej W Garbowski, Manuel Ugidos, Alberto Risueño, et al.
Haematologica|February 22, 2020
Differential RNA splicing as a potentially important driver mechanism in multiple myelomaMichael A Bauer, Cody Ashby, Christopher Wardell, et al.
Blood|August 19, 2022
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMMNicholas Stong, María Ortiz-Estévez, Fadi Towfic, et al.
Leukemia & Lymphoma|June 12, 2019
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)Anna Kalff, Tiffany Khong, Sridurga Mithraprabhu, et al.
Pageof 5